225
Views
3
CrossRef citations to date
0
Altmetric
Editorials

In pursuit of the normal progressor: the holy grail for ALS clinical trial design?

&
Pages 1-2 | Received 29 Aug 2019, Accepted 16 Sep 2019, Published online: 11 Oct 2019

References

  • Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernandez M, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;1–10.
  • Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265–7.
  • Thakore NJ, Lapin BR, Pioro EP. Pooled resource open-access ALSCTC. Trajectories of impairment in amyotrophic lateral sclerosis: insights from the pooled resource open-access ALS clinical trials cohort. Muscle Nerve. 2018;57:937–45.
  • Mandrioli J, Biguzzi S, Guidi C, Sette E, Terlizzi E, Ravasio A, et al. Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy. Neurol Sci. 2015;36:2243–52.
  • van Eijk RPA, Westeneng HJ, Nikolakopoulos S, Verhagen IE, van Es MA, Eijkemans MJC, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92:e451.
  • Edaravone Writing Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
  • Palumbo JM, Hubble J, Apple S, Takei K, Tsuda K, Liu S, et al. Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:421–31.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.